UNSPSC 51383202: Flosulide

This classification denotes a cyclooxygenase inhibitor with the molecular formula C16H13F2NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GVR41S4ZHJ, chemically known as n-(6-(2,4-difluorophenoxy)-1-oxo-5-indanyl)methanesulfonamide but generally known as flosulide, which bears US NIH Compound Identifier 71246. European Medicines Agency schedules Flosulide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07655MIG.

UNSPSC 51383202 Flosulide (Commodity) does not align with recent state and local procurement activity in the source. The three recent opportunities tagged under this code solicit naloxone and drug deactivation systems, therapeutic pharmacy initiatives for direct-to-manufacturer prescriptions, and generic multi-source pharmaceuticals and over-the-counter products — none of which are flosulide, a corticosteroid compound used in pharmaceutical formulations. The mismatch suggests either a classification error in the underlying opportunity records or a fundamental disconnect between the code's nominal scope and what state and local buyers are actually procuring under this designation. No recent solicitations for flosulide itself appear in the source material.

The issuing bodies in the source span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing consortia (Minnesota MMCAP, serving multiple state and local jurisdictions including Oregon). Activity concentrates in Florida, Texas, and Minnesota, with broader regional reach through cooperative purchasing vehicles. Representative opportunities include Seminole County's IFB60459723LAS for naloxone and drug deactivation systems (IFB, due July 26, 2023), Texas HHS Commission's HHS0017013 Request for Information on direct-to-manufacturer prescription programs (RFI, response due April 3, 2026), and MMCAP's S1070000015802 for generic pharmaceuticals and OTC products (RFP, due March 26, 2026). Given the code-to-opportunity mismatch, this Commodity code shows little relevant recent activity for business development purposes.